AZUR PHARMA INTERNATIONAL III LIMITED – Trademark Portfolio

Entity Type: 16

AZUR PHARMA INTERNATIONAL III LIMITED holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include VERSACLOZ and FAZACLO (CLOZAPINE, USP) ORALLY DISINTEGRATING TABLETS. The owner is based in HAMILTON.

CLARENDON HOUSE, 2 CHURCH STREET

HAMILTON HM11 , BM

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

AZUR PHARMA INTERNATIONAL III LIMITED's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does AZUR PHARMA INTERNATIONAL III LIMITED have?

AZUR PHARMA INTERNATIONAL III LIMITED has 5 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 abandoned, 1 cancelled.

What trademark classes does AZUR PHARMA INTERNATIONAL III LIMITED file in?

AZUR PHARMA INTERNATIONAL III LIMITED files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are AZUR PHARMA INTERNATIONAL III LIMITED's most well-known trademarks?

AZUR PHARMA INTERNATIONAL III LIMITED's registered trademark portfolio includes well-known marks such as VERSACLOZ and FAZACLO (CLOZAPINE, USP) ORALLY DISINTEGRATING TABLETS. These are among 2 currently registered trademarks in the portfolio.

What is AZUR PHARMA INTERNATIONAL III LIMITED's trademark registration success rate?

AZUR PHARMA INTERNATIONAL III LIMITED has a 40% trademark registration rate, with 2 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.